SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain , Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 10:30am

The simple and easy to use Dexcom ONE rt-CGM system is now listed on the NHS England, Wales , Scotland and Northern Ireland drug tariffs The first of Dexcom's scan-free and finger prick-free † devices available on prescription for people with Type 1 diabetes and Type 2 insulin dependent diabetes

SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2022-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022 . Second Quarter 2022 Financial Highlights: Revenue grew 17% versus the same quarter of the prior year to $696.2 million on a reported basis

Dexcom provides more choice to users by launching Spanish-language capabilities for its mobile app for the best-selling real-time CGM in the world Spanish-speaking patients can opt to use the Dexcom G6 app in their preferred language, eliminating a language barrier for optimal care SAN DIEGO

BURNABY, British Columbia --(BUSINESS WIRE)--Jul. 19, 2022-- Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by Great Place to Work Institute® Canada ,

SAN DIEGO --(BUSINESS WIRE)--Jun. 30, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022 . Management will hold a conference call to review the company's second quarter 2022 performance

This year’s Diabetes Awareness Week (13-19 June) is celebrating the triumphs and challenges for all people with diabetes. To celebrate the week, as well as the updated NICE ( National Institute of Health and Care Excellence ) guidelines, which will allow more people than ever before have access to

The expanded portfolio that includes Dexcom G6 and Dexcom G6 Pro in the U.S. and Dexcom G7 and Dexcom ONE 1 internationally, offers the most innovative, connected and accessible CGM options available for people living with diabetes around the world The portfolio is built on the unparalleled

With CGM now part of the Diabetes Canada Clinical Practice Guidelines, Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British Columbia --(BUSINESS WIRE)--Jun.

SAN DIEGO --(BUSINESS WIRE)--May 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation: “Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits